Auszug
Die seit Jahren rückläufige Verordnung der Koronarmittel hat sich auch 2006 fortgesetzt. Standardmittel zur Kupierung des akuten Angina-pectoris-Anfalls ist weiterhin Glyceroltrinitrat. Mengenmäßig bedeutsamer ist die Verordnung der Langzeitnitrate Isosorbiddinitrat (ISDN) und Isosorbidmononitrat (ISMN) sowie Molsidomin zur symptomatischen antianginösen Dauertherapie. Pentaerythrityltetranitrat (PETN) wurde auch 2006 wieder mehr eingesetzt, obwohl die aus tierexperimentellen Daten erwarteten Vorteile bisher nicht in Endpunktstudien nachgewiesen sind.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Gori T, Al-Hesayen A, Jolliffe C, Parker JD (2003): Comparison of the effects of pentaerythritol tetranitrate and nitroglycerin on endothelium-dependent vasorelaxation in male volunteers. Am J Cardiol 91: 1392–1394.
Hirayama A, Kodama K, Yui Y, Nonogi H, Sumiyoshi T, Origasa H, Hosoda S, Kawai C, Japan Multicenter Investigation for Cardiovascular Diseases-Mochida Investigators (2003): Effect of trapidil on cardiovascular events in patients with coronary artery disease (results from the Japan Multicenter Investigation for Cardiovascular Diseases-Mochida [JMIC-M]). Am J Cardiol 92: 789–793.
Jurt U, Gori T, Ravandi A, Babaei S, Zeman P, Parker JD (2001): Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol 38: 854–859.
Lehmann G, Reiniger G, Beyerle A, Schomig A (1998): Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine. J Cardiovasc Pharmacol 31: 25–30.
Maresta A, Balducelli M, Latini R, Bernardi G, Moccetti T, Sosa C, Barlera S, Varani E, Ribeiro da Silva EE, Monici Preti A, Maggioni AP; STARC II Investigators (2005): Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. Catheter Cardiovasc Interv. 64: 375–382.
Meinertz T, Lehmacher W for the Trapidil/ISDN Study Group (2006): Trapidil is as effective as isosorbidedinitrate for treating stable angina pectoris-a multinational, multicenter, double-blind, randomized study. Clin Res Cardiol. 95: 217–223.
Mest HJ (1990): Trapidil: a potent inhibitor of platelet aggregation. J Drug Dev 3: 143–149.
Wagner F, Gohlke-Barwolf C, Trenk D, Jähnchen E, Roskamm H (1991): Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris. Eur Heart J 12: 994–999.
Wenzel P, Hink U, Oelze M, Seeling A, Isse T, Brans K, Steinhoff L, Brandt M, Kleschyov AL, Schulz E, Lange K, Weiner H, Lehmann J, Lackner KJ, Kawamoto T, Munzel T, Daiber A (2007): Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH-2-/mice. Br J Pharmacol 150: 526–533.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Eschenhagen, T. (2008). Koronarmittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_33
Download citation
DOI: https://doi.org/10.1007/978-3-540-72548-0_33
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72547-3
Online ISBN: 978-3-540-72548-0
eBook Packages: Medicine (German Language)